Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving teclistamab may be safe and tolerable in treating patients with recurrent or refractory plasmablastic lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie lub cytologicznie diagnoza nawrotowego lub opornego chłoniaka plazmablastycznego
- •Mierzalne zmiany nowotworowe widoczne w badaniach obrazowych
- •Wcześniejsze leczenie - minimum 1 linia chemioterapii lub radioterapii
- •Wiek 18 lat lub więcej
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (skala ECOG ≤ 2)
- •Wystarczająca funkcja nerek (GFR ≥ 30)
- •Prawidłowe wyniki testów wątroby i krwi
- •Pacjenci z HIV lub wirusem zapalenia wątroby mogą uczestniczyć, jeśli są skutecznie leczeni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
City of Hope Comprehensive Cancer Center
Duarte, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Trial contact
Site Public Contact
James Godfrey
PRINCIPAL_INVESTIGATOR
Site Public Contact
Elizabeth A. Brem
PRINCIPAL_INVESTIGATOR
Site Public Contact
Zaw Win Myint
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kathryn Lurain
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kathleen A. Dorritie
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.